

# **Therapeutic targeting of mitochondrial dysfunction in chronic obstructive pulmonary disease (COPD)**

**by Shatarupa Das**

Thesis submitted in fulfilment of the requirements for  
the degree of

**Doctor of Philosophy**

under the supervision of  
Prof Phil Hansbro  
A/Prof Andy Philp  
Dr Matt Johansen  
Dr Nicole Hansbro

University of Technology Sydney  
Faculty of Science

December 2022

## Certificate of Original Authorship

I, ***Shatarupa Das***, declare that this thesis is submitted in fulfilment of the requirements for the award of ***Doctor of Philosophy***, in the ***School of Life Sciences*** at the University of Technology Sydney.

This thesis is wholly my own work unless otherwise referenced or acknowledged. In addition, I certify that all information sources and literature used are indicated in the thesis.

This document has not been submitted for qualifications at any other academic institution.

This research is supported by the Australian Government Research Training Program.

Production Note:

Signature: Signature removed prior to publication.

Date: 23.12.2022

## **Acknowledgement**

This thesis was a new and memorable experience for me. Words cannot express my gratitude to my supervisor and the director of Centenary UTS Centre for Inflammation, Prof. Philip Hansbro for giving me this opportunity as a PhD candidate. My gratitude extends to the Faculty of Science, for the IRS and president's scholarships to undertake my studies at the School of Life Sciences, UTS.

I also could not have undertaken this journey without my co-supervisor A/Prof. Andy Philp, who generously provided his knowledge and expertise. Additionally, this endeavour would not have been possible without the support of our Centre manager, Dr Nicole Hansbro.

I would like to express my profound gratitude to my co-supervisor Dr Matt Johansen, for his invaluable supervision, advice, continuous support, and patience during these last three years. His immense knowledge and plentiful experience have encouraged me and kept me motivated in academic research as well as in my daily life. He has been a wonderful mentor and my best friend throughout the most challenging phase of my life. His influence in shaping my experiment methods and critiquing my results has immensely helped to develop my critical thinking as a scientist. Thank you, for your kind words of encouragement that have made it possible to chase my dreams.

I would like to extend my gratitude to our past and current technical staff, Carol Devine, Simon Gao, Nimmy, and Bob Lu, for their immense hard work in the smoking facility. Special thanks to Solomon Odgers, who has put in a huge amount of work as a technical officer and now as a research assistant. In addition, I would also like to thank our other

research assistants, Dr Duc Nguyen, Dr Christina Nalkurthi, Nisha Panth, Linda Tong, and Caroline Wilson for their constant support.

My wholehearted thanks to all my peers at the Mitochondria metabolism and Ageing lab, Dr Ashleigh Philp, Dr Dean Campelj, and James Sligar with who I have greatly benefited and enjoyed working.

I am also grateful to my friends and colleagues, for being my family in Australia, thank you for all the extreme endpoint days, late-night feedback sessions and moral support. It is their kind help and support that have made my study and life in Sydney a wonderful time. Thank you, Dr Vrushali Chimankar, Dr Annalicia Vaughan, Dr Vyoma Patel, Dr Izabela Galvo, Jacqueline Marshall, Stefan Miemczyk, Hamidreza Sadegh, Tayyaba Sadaf, Angelica Katsifis, Karl Hegarty, and Vamshikrishna Malyla for all the cherished time spent together in the lab and social settings.

I would be remiss in not mentioning my family, especially my mom, and my siblings. Their belief in me has kept my spirits and motivation high during this process. Unforgotten, thank you to my late dad, whom I miss dearly. A special feeling of gratitude for my grandparents and lastly, I would also like to thank my cats for all the entertainment and emotional support.

## Summary

Chronic obstructive pulmonary disease (COPD) is characterised by airway inflammation resulting in irreversible damage to the lung, which leads to airway remodelling, alveolar destruction or emphysema, and impaired lung function. Currently, there are no available treatments that inhibit the progression or reverse the disease. Cigarette smoking (CS) is a primary cause of COPD and is an instigator of airway inflammation which is driven by oxidative stress. This further induces the over-activation of nuclear enzyme poly (ADP-ribose) polymerase-1 (PARP-1). PARP-1 is a major consumer of nicotinamide adenine dinucleotide (NAD<sup>+</sup>), a critical energy intermediate for the maintenance of all metabolic interactions.

Currently, there is limited knowledge as to how NAD<sup>+</sup> metabolism is altered in COPD and whether targeting NAD<sup>+</sup> pathways can have therapeutic benefits in COPD. Therefore, in Chapter 3, we examined the efficacy of NAD<sup>+</sup> targeted therapeutics, Nicotinamide Riboside (NR) and Pterostilbene (PT) in a prophylactic COPD model. Using our experimental CS-induced COPD mouse model, we found reduced NAD<sup>+</sup> levels associated with PARP hyperactivity in the lung. We also observed an increase in the gene expression of oxidative stress markers like NADPH-oxidase 2 (NOX2) and inflammatory markers like TNF $\alpha$  and CXCL1. Based on these findings, we hypothesised that reduced NAD<sup>+</sup> levels may instigate oxidative stress and inflammation in COPD. Thus, in Chapter 4 we investigated the therapeutic effect of NR and PT in halting the progression and reversing the disease features in COPD. Following daily dietary administration of NR and PT both prophylactically and therapeutically, we found significant reductions in inflammatory cell infiltration into the lung and reduced gene expression of inflammatory markers like TNF $\alpha$  and CXCL1. Further, NR and PT reduced airway remodelling,

emphysema, and improved lung function. NR and PT also restored NAD<sup>+</sup> levels and PARP activity in COPD. This resulted in the protection of mitochondrial structure and function via reduced oxidative stress. In conclusion, NR and PT reduced inflammation, and COPD features via increased mitochondrial function and reduced oxidative stress. Thus, NR and PT have significant potential as therapeutics for COPD.

NAD<sup>+</sup> is essential for cell survival and is tightly regulated by enzymes such as Nicotinamide mononucleotide adenyl transferases (NMNATs). NMNATs are involved in the final step of NAD<sup>+</sup> synthesis. Based on our findings from Chapter 3, imbalances in NAD<sup>+</sup> levels in COPD might be due to imbalances in NAD<sup>+</sup> synthesis. Furthermore, we determined that the administration of NR and PT in COPD increased gene expression of NMNAT1, NMNAT2 and NMNAT3. Therefore, in Chapter 5, we investigated the role of NMNATs in modulating NAD<sup>+</sup> levels in comparison to the treatment of NR and PT in COPD using transgenic NMNAT1 and NMNAT3 overexpressing mice. Additionally, we also administered NR and PT to the overexpressing NMNAT1 and NMNAT3 mice to elucidate if an additional increase in NAD<sup>+</sup> levels can potentially exhibit enhanced benefits in reducing COPD features. We found significant reductions in airway inflammation via reduced cellular infiltrates in the lung as well as a reduction in the gene expression of TNF $\alpha$  and CXCL1 with both the NMNAT1 and NMNAT3 overexpression as well as upon treatment of these mice with NR and PT. Additionally, we observed a reduction in airway remodelling and emphysema for both the NMNAT1 and NMNAT3 overexpression as well as upon treatment with NR and PT. However, there was no improvement in lung function with the overexpression of NMNAT1 and NMNAT3 mice. Additionally, treatment with NR and PT in overexpressed NMNAT1 and NMNAT3 mice further increased impaired lung function in COPD. Moreover, NMNAT1 overexpressing mice did not show an increase in the NAD<sup>+</sup>/NADH levels in COPD which did not change

with the administration of NR and PT. On the other hand, NMNAT3 overexpressing mice exhibited an increase in the NAD<sup>+</sup> levels in COPD which did not change further upon NR and PT treatment. We further observed a reduction in PARP hyperactivity with both the NMNAT1 and NMNAT3 overexpression as well as upon treatment with NR and PT, and this further showed a reduction in oxidative stress and an increase in mitochondrial membrane potential. In conclusion, we hypothesise that NMNAT3 might potentially be driving NAD<sup>+</sup> modulation to protect from COPD features. Critically, NAD<sup>+</sup> levels might potentially be rate-limiting and thus treatment of NR and PT in overexpressing NMNAT1 and NMNAT3 mice did not show a further increase in NAD<sup>+</sup> levels in COPD.

The development and progression of COPD is largely driven by chronic inflammation, however, there is limited knowledge about the exact molecular and metabolic interactions in the immune cells involved during the progression of the disease. Therefore, the objective of the Chapter 6 study was to determine if chronic CS exposure alters immunometabolism in COPD and whether pharmacological interventions can restore imbalances and exert therapeutic benefit. Using our CS-induced COPD mouse model, we determined that chronic exposure to CS reduced gene expression of pyruvate kinase markers 2 (PKM2) and Hypoxia-inducible factor 1 $\alpha$  (HIF1 $\alpha$ ) indicating reduced metabolism in the lung, while we also observed an increase in oxidative stress and inflammatory markers. Based on these findings, we hypothesised that the reduction in PKM2 may be an important driver of immunometabolism in COPD. Therefore, we next examined whether immunomodulator TEPP46, which is importantly a PKM2 activator, was able to therapeutically improve COPD disease features. Following administration of TEPP46 three times per week throughout the duration of the model, we observed a significant reduction in airway inflammation followed by reduced airway remodelling, emphysema, and improved partial lung function in COPD. TEPP46 also protected PKM2

and HIF1 $\alpha$  protein content and promoted metabolic function, resulting in reduced oxidative stress and protection of mitochondrial structure and function. In conclusion, TEPP46 has significant preclinical potential as a therapeutic for the treatment of COPD.



## List of publications and conferences

### Conference proceedings:

1. Das S., Johansen M. D., Marshall J, Sadega H., Sadaf T., Hansbro N., Thomas C., O'Neil L., Philp A., Hansbro P. M. (2022) **Investigating the therapeutic efficacy of immunomodulator TEPP46 in Chronic Obstructive Pulmonary Disease (COPD)**. In: 50<sup>th</sup> Annual Scientific Meeting of Australia and New Zealand Society for Immunology, Melbourne, Australia: 29<sup>th</sup> November-2<sup>nd</sup> December 2022.
2. Das S., Johansen M. D., Marshall J, Sadega H., Sadaf T., Hansbro N, Thomas C., O'Neil L., Philp A., Hansbro P. M. (2022) **Mitochondrial dysfunction and its modulation in Chronic Obstructive Pulmonary Disease (COPD)**. In: Australian Inflammation Centres 2022 Symposium-Virtual, Melbourne, Australia: 24<sup>th</sup>-25<sup>th</sup> November 2022.
3. Das S., Johansen M. D., Marshall J, Sadega H., Sadaf T., Hansbro N, Thomas C., O'Neil L., Philp A., Hansbro P. M. (2022) **Investigating mitochondrial dysfunction as a potential therapeutic target for Chronic Obstructive Pulmonary Disease (COPD)**. In: 16<sup>th</sup> Annual New South Wales Asthma Meeting (NAME), Sydney, Australia: 17<sup>th</sup>-18<sup>th</sup> of November 2022.
4. Das S., Johansen M. D., Marshall J, Sadega H., Sadaf T., Hansbro N, Thomas C., O'Neil L., Philp A., Hansbro P. M. (2022) **Targeting impaired immunometabolism to prevent the development of Chronic Obstructive Pulmonary Disease (COPD)**.

In: 7<sup>th</sup> biennial Australian conference for mitochondrial research AussieMit 2022, Sydney, Australia: 16<sup>th</sup>-18<sup>th</sup> of November 2022.

5. Das S., Johansen M. D., Marshall J, Sadega H., Sadaf T., Hansbro N, Thomas C., O'Neil L., Philp A., Hansbro P. M. (2022) **Investigating the therapeutic efficacy of immunomodulator TEPP46 in Chronic Obstructive Pulmonary Disease (COPD)**. In: 9<sup>th</sup> EMBL Australia Postgraduate Symposium, Melbourne, Australia: 9<sup>th</sup>-11<sup>th</sup> of November 2022.

## Table of contents

Certificate of Original Authorship .....	i
Acknowledgement .....	ii
Summary .....	iv
List of publications and conferences .....	viii
Table of contents .....	x
List of Figures .....	xvii
List of tables .....	xx
Abbreviations .....	xxii
Chapter 1. Literature review .....	29
1.1 COPD .....	29
1.1.1 Epidemiology .....	29
1.1.2 COPD pathophysiology .....	30
1.1.3 Risk factors for COPD .....	32
1.1.4 COPD exacerbations .....	32
1.1.5 Management of COPD exacerbations .....	33
1.1.6 Animal models of COPD .....	35
1.2 Inflammation and COPD .....	37
1.3 Oxidative stress in COPD .....	40
1.4 Mitochondrial dysfunction in COPD .....	41
1.5 Glycolysis .....	44
1.6 Krebs cycle .....	46
1.7 Oxidative phosphorylation and electron transport chain .....	47
1.8 NAD <sup>+</sup> , a potential therapeutic target for COPD .....	50
1.9 NAD <sup>+</sup> modulators .....	53
1.9.1 Nicotinamide Riboside (NR) .....	53
1.10 Pterostilbene .....	54
1.11 TEPP46 .....	55
1.12 Study rationale .....	58
Chapter 2. General materials and methods .....	59
2.1 General reagents .....	59
2.1.1 Nuclease-free water .....	59
2.1.2 MilliQ water .....	59
2.1.3 Ethanol (70% v/v) .....	59

2.1.4	Phosphate buffered saline (PBS) (1X)	59
2.1.5	Phosphate buffered saline – Tween-20 (PBST) (1X) (0.5%)	60
2.1.6	Sodium Chloride (NaCl) (0.9%)	60
2.2	Animal models	60
2.2.1	Ethics statement	60
2.2.2	Experimental mice model	60
2.2.3	Smoke inhalation system	61
2.2.4	Preparation and exposure of mice to cigarette smoke	61
2.2.5	Euthanasia	63
2.2.6	Blood and Serum	63
2.2.7	BAL	64
2.2.8	Differential counts on BAL	65
2.2.9	Processing of lung samples for histopathological analysis	65
2.2.10	Hematoxylin and Eosin stain	66
2.2.11	Sirius red and fast green stain	67
2.2.12	Lung function	67
2.2.13	Lung function analysis	69
2.2.14	Immunofluorescence staining	69
2.2.15	Transmission Electron microscopy	71
2.2.16	RNA extraction	74
2.2.17	cDNA preparation	75
2.2.18	Quantitative PCR	75
2.2.19	Gene expression	76
2.2.20	Analysis of qPCR experiments	79
2.2.21	Protein isolation and quantitation	80
2.2.22	Detergent Compatible (DC) assay	80
2.2.23	Western blotting	81
2.2.24	PK activity	84
2.2.25	Pyruvate Dehydrogenase (PDH) activity	85
2.2.26	NAD <sup>+</sup> /NADH measurement	85
2.2.27	PARP activity measurement	86
2.2.28	Mitochondrial respiratory chain activity assay	87
2.2.29	Measurement of Mitochondria membrane potential ( $\Delta\Psi_m$ )	94
2.2.30	Statistical analysis	95

Chapter 3. Elucidating the therapeutic implications of NR and/or PT in preventing the progression of COPD in vivo .....	96
3.1 Introduction .....	96
3.2 Methodology .....	98
3.2.1 Experimental COPD model .....	98
3.2.2 Experimental procedure .....	98
3.2.3 Experimental designs .....	98
3.2.4 Experimental groups .....	100
3.3 Results .....	102
3.3.1 Imbalance in NAD <sup>+</sup> homeostasis during the development of COPD .....	102
3.3.2 Administration of NR and/or PT reduced inflammation in acute CS exposure	103
3.3.3 Administration of NR and PT restores NAD <sup>+</sup> /NADH balance in acute CS exposure	106
3.3.4 Administration of NR and/or PT reduced hyperactivity of NAD <sup>+</sup> consumers in acute CS exposure .....	109
3.3.5 Administration of NR and PT reduced airway inflammation in COPD ..	111
3.3.6 Administration of NR and/or PT attenuated airway remodelling and emphysema in COPD .....	114
3.3.7 Administration of NR and/or PT improved lung function in COPD .....	115
3.3.8 Administration of NR and/or PT regulated NAD <sup>+</sup> /NADH levels in COPD	118
3.3.9 Administration of NR and/or PT regulated NAD <sup>+</sup> consumers in COPD	121
3.3.10 Administration of NR and/or PT preserved mitochondrial structure in COPD	127
3.3.11 Administration of NR and/or PT preserved mitochondrial cristae structure in COPD.....	130
3.3.12 Administration of NR and/or PT promoted mitochondrial function in COPD	132
3.3.13 Administration of NR and/or PT promoted mitochondrial membrane potential in COPD.....	135
3.3.14 Administration of NR and/or PT reduced oxidative stress in COPD.....	137
3.4 Discussion .....	139
Chapter 4. Investigating the role of NR and PT in reversing or delaying the progression of COPD .....	147
4.1 Introduction .....	147
4.2 Methodology .....	149

4.2.1	Experimental COPD model .....	149
4.2.2	Experimental procedure of smoking: .....	149
4.2.3	Experimental designs .....	149
4.3	Results .....	153
4.3.1	Administration of NR and PT reduced inflammation in advanced COPD 153	
4.3.2	Administration of NR and PT attenuated COPD features in advanced diseases stages .....	156
4.3.3	Administration of NR and PT increased NAD <sup>+</sup> levels in advanced COPD 159	
4.3.4	Administration of NR and PT regulated PARPs and CD38 in COPD....	162
4.3.5	Administration of NR and PT regulated SIRT1s in advanced COPD .....	164
4.3.6	Administration of NR and PT protected mitochondrial structure in advanced COPD.....	168
4.3.7	Administration of NR and PT preserved mitochondrial cristae structure in COPD	172
4.3.8	Administration of NR and PT restored mitochondrial function in advanced COPD	174
4.3.9	Administration of NR and PT restored mitochondrial membrane potential in COPD.....	178
4.3.10	Administration of NR and PT reduced oxidative stress in advanced COPD 181	
4.3.11	Administration of NR and PT reduced inflammation in advanced COPD 183	
4.3.12	Administration of NR and PT attenuated COPD features in advanced disease stages .....	185
4.3.13	Administration of NR and PT restored NAD <sup>+</sup> levels in COPD.....	189
4.3.14	Administration of NR and PT regulated PARP and CD38 in advanced COPD	190
4.3.15	Administration of NR and PT regulated SIRT1s in COPD .....	192
4.3.16	Administration of NR and PT restored mitochondrial structure in advanced COPD.....	194
4.3.17	Administration of NR and PT preserved mitochondrial cristae structure in advanced COPD.....	197
4.3.18	Administration of NR and PT restored mitochondrial function in advanced COPD	199
4.3.19	Administration of NR and PT restored mitochondrial membrane potential in advanced COPD .....	202

4.3.20	Administration of NR and PT reduced oxidative stress in advanced COPD	205
4.4	Discussion .....	207
Chapter 5.	Therapeutic targeting of NAD <sup>+</sup> modulation in COPD using overexpressed NMNAT1 and NMNAT3 <i>in vivo</i> .....	216
5.1	Nicotinamide mononucleotide adenylyl transferases (NMNATs) isoforms .....	216
5.1.1	Generation of transgenic NMNAT1 and NMNAT3 overexpressed mice	218
5.1.2	Study rationale .....	218
5.2	Methodology .....	220
5.2.1	Experimental COPD model .....	220
5.2.2	Experimental procedure .....	220
5.2.3	Experimental designs .....	220
5.2.4	Experimental groups .....	222
5.3	Results .....	224
5.3.1	Administration of NR and PT in COPD promoted increased expression of NMNAT1 and NMNAT3 .....	224
5.3.2	Overexpression of NMNAT1 reduced inflammation in COPD.....	226
5.3.3	Overexpression of NMNAT1 protected from airway remodelling and emphysema in COPD .....	228
5.3.4	Overexpression of NMNAT1 protects from impaired lung function in COPD	231
5.3.5	Effect of NMNAT1 overexpression on NAD <sup>+</sup> biosynthesis in COPD ...	236
5.3.6	NMNAT1 overexpression regulated NAD <sup>+</sup> consumers in COPD.....	238
5.3.7	NMNAT1 overexpression increased mitochondria membrane potential in COPD	242
5.3.8	NMNAT1 overexpression protected from oxidative stress in COPD.....	247
5.3.9	NMNAT3 overexpression reduced inflammation in COPD.....	251
5.3.10	NMNAT3 overexpression protected from airway remodelling and emphysema in COPD .....	253
5.3.11	Overexpression of NMNAT3 protects from impaired lung function in COPD	257
5.3.12	NMNAT3 overexpression regulated NAD <sup>+</sup> biosynthesis in COPD .....	262
5.3.13	NMNAT3 overexpression regulated NAD <sup>+</sup> consumers in COPD.....	264
5.3.14	NMNAT3 overexpression increased mitochondria membrane potential	267
5.3.15	NMNAT3 overexpression reduced oxidative stress in COPD.....	271
5.4	Discussion .....	276

Chapter 6. Investigating the therapeutic efficacy of immunomodulator TEPP46 in Chronic Obstructive Pulmonary Disease (COPD).....	288
6.1 Introduction .....	288
6.2 Methods .....	290
6.2.1 Experimental designs and groups .....	290
6.3 Results .....	293
6.3.1 Oxidative stress and mitochondrial dysfunction drive impaired metabolism in experimental COPD model .....	293
6.3.2 Administration of TEPP46 reduced inflammatory cell influx in acute CS exposure.....	297
6.3.3 Administration of TEPP46 protected from alveolar damage during acute CS exposure .....	300
6.3.4 TEPP46 promoted tetramerisation of PKM2 in acute CS exposure .....	301
6.3.5 Administration of TEPP46 promoted the metabolic role of PKM2.....	303
6.3.6 TEPP46 promoted mitochondria membrane potential ( $\Delta\Psi_m$ ) during acute CS exposure .....	305
6.3.7 Administration of TEPP46 reduced inflammation in experimental COPD model .....	307
6.3.8 Administration of TEPP46 protected from COPD features in experimental COPD studies.....	310
6.3.9 Administration of TEPP46 promoted tetramerisation of PKM2 in experimental COPD model.....	313
6.3.10 Administration of TEPP46 promoted the metabolic role of PKM2 in experimental COPD study .....	314
6.3.11 Administration of TEPP46 improved NAD <sup>+</sup> metabolism in the experimental COPD model.....	317
6.3.12 Administration of TEPP46 protected from oxidative stress in experimental COPD model.....	320
6.3.13 Administration of TEPP46 preserved mitochondrial ultra-structure in experimental COPD .....	324
6.3.14 Administration of TEPP46 promoted oxidative phosphorylation and $\Delta\Psi_m$ in experimental COPD.....	326
6.4 Discussion .....	329
Chapter 7. General Discussion .....	339
7.1 Introduction .....	339
7.2 Experimental findings .....	340
7.2.1 Imbalance in NAD <sup>+</sup> homeostasis .....	340
7.2.2 Targeting impaired NAD <sup>+</sup> homeostasis using NR and PT in COPD.....	341



7.2.3	Implications of NR and PT in advanced COPD stages.....	344
7.2.4	Therapeutic targeting of NAD <sup>+</sup> compartmentalisation in COPD .....	347
7.2.5	Implications of NR and PT in transgenically overexpressed NMNAT1 and NMNAT3 in COPD .....	349
7.2.6	Impairment of PKM2 in COPD .....	352
7.2.7	Targeting impaired PKM2 using TEPP46 in COPD .....	353
7.3	Conclusion.....	355
7.4	Future directions.....	359
7.5	References .....	361

## List of Figures

Figure 1.1: The Warburg effect.....	39
Figure 1.2: CS exposure in COPD .....	43
Figure 1.3: Glycolysis: .....	45
Figure 1.4: Krebs cycle .....	47
Figure 1.5: The electron transport chain .....	49
Figure 1.6: NAD biosynthesis and consumption .....	52
Figure 1.7: Tetramerisation of PKM2 by TEPP46 .....	57
Figure 2.1: Smoke inhalation system:.....	61
Figure 2.2: CS exposure of mice.....	63
Figure 3.1: Experimental design .....	99
Figure 3.2: Imbalance in NAD <sup>+</sup> homeostasis during the development of COPD:.....	102
Figure 3.3: Administration of NR and/or PT reduced inflammation in acute CS exposure: .....	106
Figure 3.4: Administration of NR and/or PT restored imbalance in NAD <sup>+</sup> homeostasis in acute CS exposure:.....	109
Figure 3.5: : Administration of NR and/or PT reduced hyperactivity of NAD <sup>+</sup> consumers in acute CS exposure:.....	111
Figure 3.6: Administration of NR and/or PT reduced airway inflammation in COPD:.....	113
Figure 3.7: Administration of NR and/or PT attenuates airway remodelling and emphysema in COPD:.....	115
Figure 3.8: Administration of NR and/or PT improved lung function in COPD: .....	118
Figure 3.9: Administration of NR and/or PT restored imbalance of NAD <sup>+</sup> homeostasis in COPD:.....	121
Figure 3.10: Administration of NR and/or PT regulates NAD <sup>+</sup> consumers in COPD:.....	126
Figure 3.11: Administration of NR and/or PT preserved mitochondrial structure in COPD:.....	129
Figure 3.12: Administration of NR and/or PT preserved mitochondrial cristae structure in COPD:.....	131
Figure 3.13: Administration of NR and/or PT promotes mitochondrial function in COPD:.....	134
Figure 3.14: Administration of NR and/or PT promoted mitochondrial membrane potential in COPD:.....	136
Figure 3.15: Administration of NR and PT reduces oxidative stress in COPD:.....	138
Figure 4.1: Progressive treatment approaches for COPD .....	148
Figure 4.2: Experimental design for 12-week advanced COPD study: .....	152
Figure 4.3: Administration of NR and PT restored inflammation in advanced COPD:.....	155
Figure 4.4: Administration of NR and PT attenuated COPD features:.....	159
Figure 4.5: Administration of NR and PT increased NAD <sup>+</sup> levels in advanced COPD: .....	161
Figure 4.6: Administration of NR and PT restored PARP and CD38 levels in COPD:.....	163
Figure 4.7: Administration of NR and PT regulated SIRT6 in advanced COPD: .....	168
Figure 4.8: Administration of NR and PT protected mitochondrial structure in advanced COPD:.....	171
Figure 4.9: Administration of NR and PT protected mitochondrial cristae structure in advanced COPD:.....	174

Figure 4.10: Administration of NR and PT promoted mitochondrial function in advanced COPD:.....	177
Figure 4.11: Administration of NR and PT restored mitochondria membrane potential in advanced COPD:.....	180
Figure 4.12: Administration of NR and PT reduces oxidative stress in advanced COPD:.....	182
Figure 4.13: Administration of NR and PT restored inflammation in COPD: .....	185
Figure 4.14: Administration of NR and PT restored COPD features in advanced disease stages:.....	188
Figure 4.15: Administration of NR and PT restored NAD <sup>+</sup> homeostasis in advanced COPD:.....	190
Figure 4.16: Administration of NR and PT regulated PARP and CD38 levels in COPD .....	191
Figure 4.17: Administration of NR and PT regulates SIRT6 in advanced COPD studies:.....	194
Figure 4.18: Administration of NR and PT restored mitochondrial structure in advanced COPD:.....	196
Figure 4.19: Administration of NR and PT restored mitochondrial cristae structure in advanced COPD:.....	198
Figure 4.20: Administration of NR and PT promoted mitochondrial function in advanced COPD:.....	201
Figure 4.21: Administration of NR and PT restored mitochondria membrane potential in advanced COPD:.....	204
Figure 4.22: Administration of NR and PT reduces oxidative stress in COPD:.....	206
Figure 5.1: NMNAT isoforms .....	217
Figure 5.2: Experimental design of NMNAT1/3 overexpressed mice: .....	221
Figure 5.3: Administration of NR and PT increased the gene expression of NMNAT1 and NMNAT3: .....	225
Figure 5.4: NMNAT1 overexpression reduced airway inflammation in COPD: .....	227
Figure 5.5: NMNAT1 overexpression protected from airway remodelling and emphysema in COPD:.....	230
Figure 5.6: NMNAT1 overexpression protected from impaired lung function in COPD:.....	235
Figure 5.7: Effect of NMNAT1 overexpression on NAD <sup>+</sup> biosynthesis in COPD: .....	238
Figure 5.8: NMNAT1 overexpression regulated NAD <sup>+</sup> consumers in COPD: .....	242
Figure 5.9: NMNAT1 overexpression increase $\Delta\Psi_m$ in COPD:.....	246
Figure 5.10:NMNAT1 overexpression reduced oxidative stress in COPD: .....	250
Figure 5.11: NMNAT3 overexpression reduced airway inflammation in COPD: .....	253
Figure 5.12: NMNAT3 overexpression protected from airway remodelling and emphysema in COPD:.....	256
Figure 5.13: NMNAT3 overexpression protected from impaired lung function in COPD:.....	261
Figure 5.14: Effect of NMNAT3 overexpression on NAD <sup>+</sup> biosynthesis in COPD: ...	264
Figure 5.15: NMNAT3 overexpression regulated NAD <sup>+</sup> consumers in COPD: .....	266
Figure 5.16: NMNAT3 overexpression increased mitochondria membrane potential in COPD:.....	270

Figure 5.17: NMNAT3 overexpression reduced oxidative stress in COPD:.....	274
Figure 6.1: Experimental design: .....	292
Figure 6.2: Oxidative stress is the potential driver of inflammation in experimental COPD:.....	296
Figure 6.3: Administration of TEPP46 reduced inflammation in acute CS exposed model:.....	299
Figure 6.4: Administration of TEPP46 protected from alveolar damage during acute CS exposure: .....	301
Figure 6.5: TEPP46 promoted tetramerisation of PKM2 in acute CS exposed inflammation: .....	302
Figure 6.6 Administration of TEPP46 promoted the metabolic role of PKM2 in COPD: .....	305
Figure 6.7: Administration of TEPP46 promoted mitochondrial function during acute CS exposure: .....	307
Figure 6.8: Administration of TEPP46 reduced inflammation in experimental COPD model:.....	309
Figure 6.9: Administration of TEPP46 protected from COPD features: .....	312
Figure 6.10: TEPP46 promoted tetramerisation of PKM2: .....	314
Figure 6.11: TEPP46 promoted the metabolic role of PKM2:.....	317
Figure 6.12: TEPP46 improved NAD <sup>+</sup> metabolism in experimental COPD:.....	319
Figure 6.13: TEPP46 protects from oxidative stress in COPD:.....	323
Figure 6.14: Administration of TEPP46 protected mitochondrial ultra-structure in experimental COPD: .....	325
Figure 6.15: Administration of TEPP46 promoted mitochondrial function in experimental COPD: .....	328
Figure 7.1: Therapeutic intervention of NR, PT and TEPP46 in COPD: .....	358

## List of tables

Table 1.1: GOLD classification of COPD .....	30
Table 2.1: RBC lysis buffer formulation .....	64
Table 2.2: Citrate EDTA Buffer (pH 6.2) .....	70
Table 2.3: List of primary antibodies used in immunofluorescence staining .....	70
Table 2.4: Recipe for 0.4M sodium cacodylate buffer.....	72
Table 2.5: Recipe for 0.2M sodium cacodylate buffer.....	72
Table 2.6: Recipe for 0.1M sodium cacodylate buffer.....	73
Table 2.7: Recipe for 2.5% glutaraldehyde working solution .....	73
Table 2.8: Recipe for 1% osmium tetroxide .....	73
Table 2.9: Recipe for 2% uranyl acetate .....	73
Table 2.10: Primer sequences .....	76
Table 2.11: Reaction mix for protein quantitation using DC assay .....	81
Table 2.12: Recipe for loading buffer (4X) .....	82
Table 2.13: Recipe for SDS running buffer (1X).....	82
Table 2.14: Recipe for Transfer buffer (1X) (pH-8.3).....	82
Table 2.15: Recipe for blocking buffer .....	83
Table 2.16: Recipe for TBST wash buffer (1X) (pH-7.6).....	83
Table 2.17: Recipe for Stripping buffer (1X) (pH-2.34).....	83
Table 2.18: List of primary antibodies .....	83
Table 2.19: Reaction mix for measuring PK activity.....	84
Table 2.20: Reaction mix for measurement of PDH activity .....	85
Table 2.21: Reaction mix for NAD <sup>+</sup> /NADH measurement .....	86
Table 2.22: Sample preparation for PARP activity measurements.....	87
Table 2.23: Recipe for PARP cocktail .....	87
Table 2.24: Stock reagent recipe for Mitochondrial respiratory chain activity assay.....	88
Table 2.25: Protocol for measurement of mitochondrial ETC complex I activity.....	89
Table 2.26: Protocol for measurement of mitochondrial ETC complex II activity .....	90
Table 2.27: Protocol for measurement of mitochondrial ETC complex III activity .....	90
Table 2.28: Protocol for measurement of mitochondrial ETC complex IV activity.....	91
Table 2.29: Protocol for measurement of mitochondrial ETC complex I + III activity .	92
Table 2.30: Protocol for measurement of mitochondrial ETC complex II+ III activity .	92
Table 2.31: Protocol for measurement of mitochondrial citrate synthase activity .....	93
Table 2.32: Protocol for measurement of $\beta$ -HAD activity.....	94
Table 3.1: Experimental groups of the 2-week COPD study.....	100
Table 3.2: Experimental groups of the 8-week COPD study.....	101
Table 4.1: Experimental groups in 12-week model-1 .....	150
Table 4.2: Experimental groups in 12-week model-2 .....	151
Table 5.1: Experimental groups of the WT/NMNAT1 8-week COPD study.....	222
Table 5.2: Experimental groups of the WT/NMNAT3 8-week COPD study.....	223
Table 6.1: Experimental groups of 2-week TEPP46 study .....	291
Table 6.2: Experimental groups of 8-week TEPP46 study .....	291
Table 7.1: Benefits of NR and/or PT in COPD.....	343
Table 7.2: Therapeutic implications of NR and PT in advanced stages of COPD .....	346
Table 7.3: Elucidating the role of overexpressed NMNAT1 and NMNAT3 in COPD	349

Table 7.4: Implications of NR and PT on overexpressed NMNAT1 and NMNAT3 mice in COPD.....	351
Table 7.5: Therapeutic potential of immunomodulator TEPP46 in COPD .....	354

## Abbreviations

°C	Degrees Celsius
β-HAD	β-hydroxyacyl CoA
ΔΨ <sub>m</sub>	Mitochondria membrane potential
μg	Microgram
μl	Microlitre
μm	Micrometre
4-HNE	4-hydroxy-2-nonenal
3-NT	3-nitrotyrosine
A	estimation of IC
AATD	α-1-antitrypsin deficiency
AAt	α-1-antitrypsin
Acetyl-CoA	Acetyl coenzyme A
ADP	Adenosine diphosphate
ALS	amyotrophic lateral sclerosis
ARC	Animal Resources Centre
ATP	Adenosine triphosphate
BAL	Bronchoalveolar lavage
BSA	Bovine serum albumin

CO <sub>2</sub>	Carbon dioxide
COPD	Chronic obstructive pulmonary disease
CRS	Respiratory system compliance
CS	Cigarette smoke
Cst	Static compliance
CXCL1	Chemokine ligand 1
DBQ	Decyl ubiquinone
DC	Detergent Compatible
DMSO	Dimethyl sulfoxide
DPBS	Dulbecco's Phosphate-Buffered Saline
DTNB	5,5-dithio-bis-(2-nitrobenzoic acid)
EC	Endothelial cells
ETC	Electron transport chain
FADH <sub>2</sub>	Flavin adenine dinucleotide
FEV	Forced expiratory volume
FRC	Functional residual capacity
FVC	Forced vital capacity
FITC	Fluorescein Isothiocyanate
G	Tissue damping
GCN5	Gene control non-derepressible 5



GOLD	Global Initiative on Chronic Obstructive Lung Disease
GLUT1	Glucose transporter 1
H	Tissue elastance
H <sub>2</sub> O <sub>2</sub>	Hydrogen peroxide
HCL	Hydrochloric acid
HDAC2	Histone deacetylase 2
HIF1 $\alpha$	Hypoxia inducing factor-1 $\alpha$
HK1	Hexokinase-1
HO1	Heme oxygenase 1
HPRT	Hypoxanthine-guanine phosphoribosyl transferase
IC	Inspiratory capacity
IL-1 $\beta$	Interleukin-1 $\beta$
ICAM1	Intermolecular adhesion molecule
iNOS	Inducible nitric oxide synthase
KCN	Potassium cyanide
Kpi	Potassium phosphate
LDHA	Lactate dehydrogenase A
LPS	Lipopolysaccharide
LTB4	Leukotriene B4
MMP-12	matrix metalloproteinase-12

MLI	Mean linear intercepts
mtROS	Mitochondrial reactive oxygen species
mtRNS	Mitochondrial reactive nitrogen species
NA	Nicotinic acid
NaCl	Sodium chloride
NAD <sup>+</sup>	Nicotinamide adenine dinucleotide
NAAD	Nicotinic acid adenine dinucleotide
NADK1/2	NAD <sup>+</sup> kinase 1/2
NADH	Nicotinamide adenine dinucleotide
NADSYN	NAD <sup>+</sup> synthase
NAFLD	Non-alcoholic fatty liver disease
NAM	Nicotinamide
NAMN	Nicotinic acid mononucleotide
NAMPT	Nicotinamide phosphoribosyl transferase
NAPRT	Nicotinate phosphoribosyl transferase
NF- $\kappa\beta$	Nuclear factor- $\kappa\beta$
NHMRC	National Health and Medical Research Council of Australia
NMN	Nicotinamide mononucleotide
NMNT	Nicotinamide mononucleotide transferase

NMNATs	Nicotinamide mononucleotide adenylyl transferase
NK	Natural killer cells
NOX2	NADHP oxidase
Nrf2	Nuclear factor erythroid 2-related factor-2
NR	Nicotinamide riboside
NRKs	Nicotinamide ribose kinases
NTHi	Non-typeable Haemophilus influenzae
O <sup>-</sup>	Superoxide
Oct-4	Octamer binding transcription factor-4
Oxphos	Oxidative phosphorylation
Oxstress	Oxidative stress
PARPs	Poly (ADP-ribose) polymerases
PBS	Phosphate buffer saline with tween
PDK1	3-Phosphoinositide-dependent kinase 1
PDH	Pyruvate dehydrogenase
PEP	Phosphoenol pyruvate
PGC1 $\alpha$	Peroxisome proliferator-activated receptor-gamma co-activator 1 $\alpha$
PK	Pyruvate Kinase
PKF	Phosphofructokinase

PNP	Purine Nucleoside Phosphorylase
qPCR	Quantitative PCR
RBC	Red blood cell
ROS	Reactive oxygen species
Rn	central airway resistance
RNS	Reactive nitrogen species
Rrs	Transpulmonary resistance
RV	Residual volume
SARS-CoV-2	Severe Acute Respiratory Syndrome Coronavirus 2
SEM	Standard error mean
SIRTs	Sirtuins
SLHD	Sydney Local Health District
STAT3	Signal transducer and activator of transcription 3
TBST	Tris buffer saline with tween
TCA	Tricarboxylic acid
TEM	Transmission emission microscopy
TMPRSS2	Transmembrane serine protease 2
TNF $\alpha$	Tumour necrosis factor $\alpha$
TLC	Total lung capacity
TRP	Tryptophan

UNSW	University of New South Wales
UPRmt	Mitochondrial unfolded protein responses
VC	Vital capacity
YM1	chitinase-like protein 3